Ivermectin inhibiting SARS-2 replication enzyme 3CLpro (Mody et al, edited)
New insights into the mode of action of ivermectin against the SARS-2 coronavirus.
The previously discussed, WHO-sponsored meta-analysis of ivermectin against covid-19 has now been published as a preprint. It found a highly significant 75% reduction in covid mortality, based on randomized controlled trials only, and will be continually updated with additional trial results.
To date, the mode of action of ivermectin against the SARS-2 coronavirus has remained somewhat of a mystery. Early studies indicated that ivermectin may inhibit viral protein transportation. But a new US-Canadian study, published in Nature Commincations Biology, found that ivermection is highly effective (90%) in inhibiting the main enzyme (3CLpro) involved in the replication of the SARS-2 virus (and other RNA viruses). This might explain why ivermectin appears to be highly effective even as a prophylaxis against SARS-2 coronavirus infection.
Nevertheless, many patients, and even doctors, continue to be denied access to low-cost and safe ivermectin, especially in Western countries. Others are paying obscenely overcharged prices, visit dubious online merchants, or resort to animal-grade products. Given the current global covid death rate of 15,000 people per day, the SPR Collaboration has decided to provide access to a certified Indian pharmaceutical exporter of ivermectin, vetted by SPR readers: Kachhela Medex Ltd.
100 tablets of 12mg ivermectin, enough to treat up to 50 people, cost about $50. And even if the coronavirus continues to mutate, ivermectin, targeting its replication, will remain effective.
Note: Patients are asked to consult a doctor.
Ivermectin: Modes of action against SARS-2 virus replication (Mody et al) See also